“The first quarter of 2024 was positive and active for
Martin Jönsson, CEO
Financial information for January – March, 2024
Figures in parentheses refer to the corresponding period of the previous year.
- Net sales during the period totaled
SEK 0 thousand (0). - Loss for the period totaled
SEK -9,804 thousand (-9,545). - Earnings per share, basic, totaled
SEK -0.16 (-0.15). - Cash flow from operating activities totaled
SEK -10,063 thousand (28,095). - Total assets at the end of the period amounted to
SEK 22,688 thousand (57,974). - Cash and cash equivalents at the end of the period totaled
SEK 19,037 thousand (53,718).
Significant events during the period January – March, 2024
- On
January 29 , the company selects a drug candidate and enters the next phase of development with TrkA-NAM ACD137 for the treatment of osteoarthritis and other severe pain conditions. - On
February 29 , the company announces that the patent offices inChina ,India ,South Africa ,Israel ,Hong Kong andMexico have granted patents covering the company’s clinical drug candidate ACD856, which is being developed for Alzheimer’s and other cognitive disorders. - On
March 26 , the company’s Board of Directors resolved on a new issue of shares of approximatelySEK 52.8 million with preferential rights for existing shareholders. The Rights Issue is subject to approval by the Extraordinary General Meeting onApril 25, 2024 . The issue is guaranteed to approximately 63 percent through subscription commitments and guarantee commitments from existing owners and members of the company’s management and Board of Directors, among others. To enable further capital injections, the Board of Directors may also exercise an overallotment option of up to approximatelySEK 15.0 million . - On
March 26 , the company announces that an Extraordinary General Meeting will convene onApril 25, 2024 .
Significant events after the end of the period
- On
April 10 , the company announces that its Annual General Meeting will convene onMay 14, 2024 . - On
April 10 , the company announces that Dr.Jan Lundberg , former head of research at Eli Lilly andAstraZeneca , is investing in AlzeCure and proposes that he be elected to serve on the company’s Board of Directors.
The full report is attached as PDF and is available on the company’s website: www.alzecurepharma.com/en/section/investors/financial-reports/
© Modular Finance, source